This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad Genetics' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Given the continued performance of these initiatives, we’ve decided to increase our guidance for fiscal 2012, for the second time this year. Revenue is now expected to be in the range of $492 million to $496 million, which represents 22% to 23% growth over the prior fiscal year. Diluted earnings per share guidance has also been increased to $1.29 to $1.31 representing a 17% to 19% growth over fiscal 2011.

These strong results have positioned us well for continued success, particularly when combined with the strategic directives that we are focusing on for long term growth. Myriad is dedicated to improving patient care through the development and marketing of transformative tests across multiple medical specialties, which do have present clinical needs. With this strategy in mind we’ve put forward the following three strategic directives. One to grow existing tests and markets, two to expand our business internationally, and three to launch new transformative products including companion diagnostic tests across a diverse set of major disease indications.

Our international strategic initiatives continue to proceed ahead of schedule. Our five country managers and clinical affairs team have concluded the orientation and training program in Salt Lake City, and have now returned to their home countries to focus on growing Myriad’s presence in Germany, Switzerland, Italy, Spain and France.

During the third quarter, Myriad hosted a personalized Medicine Symposium and ribbon cutting ceremony at the Company’s new laboratory in Munich, Germany. Approximately 100 physicians, scientists, politicians and journalists attended the event, and heard presentation on the latest advancements and companion diagnostics and personalized medicine including recent results in melanoma and prostrate cancer research.

In addition to Gary King and me, the presenters included Dr. Horst Domdey, the Director of the Bavarian Biotech Cluster; Dr. Thorston Zenz, Professor of the National Center for Tumor Diseases at Heidelberg; and Dr. Helmuth Kotter, Director of the Medical Laboratory at the University of Innsbruck. The event was extremely well received and represented an important step from Myriad in building relationships in region, and increasing our visibility among the key opinion leaders in Europe.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs